• news.cision.com/
  • Dicot AB (publ)/
  • Dicot’s rights issue is registered – paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Dicot’s rights issue is registered – paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Report this content

Press release: Uppsala, November 22, 2021. Dicot AB (publ) (”Dicot” or the "Company") has carried out a rights issue of units to an amount of approximately MSEK 25.3 (“the Rights Issue”). The Rights Issue was completed on October 27, 2021. The Rights Issue was subscribed to 97.9 percent. Through the Rights Issue, the Company obtains approximately MSEK 24.7 before issue costs.

The Rights Issue is now registered with the Swedish Companies Registration Office. The last day of trading in paid subscription units (BTU) is November 24, 2021. The record date is November 26, 2021; after this day, BTU will be converted to shares and warrants. The newly issued shares and warrants are expected to be delivered to the shareholders' securities deposit/vp-accounts on November 30, 2021. Trading of warrants of series 2021/2022 on Spotlight Stock Market will commence on November 30, 2021.

Through the Rights Issue, Dicot’s share capital will increase by SEK 4,758,557.625 through the issuance of 38,068,461 shares. Following the registration of the Rights Issue with the Swedish Companies Registration Office, the Company’s share capital amounts to SEK 12,862,525.745 and the total number of shares in the Company amounts to 102,900,206 shares.


Through the Rights Issue, the Company also issues 38,068,461 warrants of series 2021/2022, which entitle to subscribe for 38,068,461 shares in the Company.

The warrants of series 2021/2022 that have been issued through the Rights Issue entitle the holder to subscribe for one (1) new share in Dicot during the subscription period from June 1, 2022 through June 15, 2022. The subscription price for shares using the warrants will correspond to 70 percent of the volume weighted average price of the Company's shares according to the Spotlight Stock Market official price list for the period from May 16, 2022 through May 27, 2022 but will not be higher than SEK 1.50 or less than SEK 0.125 (corresponding to the quota value of the Company’s shares).

Upon full exercise of all warrants of series 2021/2022 within the framework of issued units, the Company may receive up to an additional MSEK 57.1, depending on the exercise price. Upon full exercise of all warrants of series 2021/2022, the share capital will increase by an additional SEK 4,758,557.625.


Stockholm Corporate Finance AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company. Hagberg & Aneborn Fondkommission AB is the issuing agent in the Rights Issue.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: goran.beijer@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.

Important information

This press release is not an offer to subscribe for shares, warrants, or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus that Dicot has published on its website on October 8, 2021 (as well as the supplement prospectus that Dicot has published on its website on October 20, 2021).

Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law. Hence, this press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.

There is no intention to apply for approval of any offer to the public in any other country within the European Economic Area (“EES”) than Sweden and the securities issued in the Rights Issue will not be offered to the public in these countries.

This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.